Seroatlas · Human Serome Atlas

FGF9

Fibroblast growth factor 9

Also known as: FGF9_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P31371
Gene
FGF9
Ensembl
ENSG00000102678
Chromosome
13
Canonical length
208 aa
Protein class
Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins
Secretome location
Secreted in other tissues
Quaternary structure
Homodimer

OverviewNCBI Gene

The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. This protein was isolated as a secreted factor that exhibits a growth-stimulating effect on cultured glial cells. In nervous system, this protein is produced mainly by neurons and may be important for glial cell development. Expression of the mouse homolog of this gene was found to be dependent on Sonic hedgehog (Shh) signaling. Mice lacking the homolog gene displayed a male-to-female sex reversal phenotype, which suggested a role in testicular embryogenesis. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

208 residues, UniProt reviewed canonical sequence.

>P31371|FGF9
     1  MAPLGEVGNY FGVQDAVPFG NVPVLPVDSP VLLSDHLGQS EAGGLPRGPA VTDLDHLKGI
    61  LRRRQLYCRT GFHLEIFPNG TIQGTRKDHS RFGILEFISI AVGLVSIRGV DSGLYLGMNE
   121  KGELYGSEKL TQECVFREQF EENWYNTYSS NLYKHVDTGR RYYVALNKDG TPREGTRTKR
   181  HQKFTHFLPR PVDPDKVPEL YKDILSQS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FGF9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.39
Highest tissue expression
11 nTPM

Expression across tissuesHPA

Tissue

  • cerebellum: 11 nTPM
  • kidney: 10 nTPM
  • retina: 7.6 nTPM
  • adrenal gland: 3.9 nTPM
  • cerebral cortex: 3.8 nTPM
  • heart muscle: 2.5 nTPM

Single-cell type

  • müller glia: 223 nCPM
  • renal collecting duct intercalated cells: 130 nCPM
  • distal convoluted tubule cells: 100 nCPM
  • retinal ganglion cells: 97 nCPM
  • loop of henle epithelial cells: 77 nCPM
  • endometrial luminal cells: 68 nCPM

Immune cell

  • naive B-cell: 0.3 nTPM
  • memory CD4 T-cell: 0.2 nTPM
  • memory CD8 T-cell: 0.2 nTPM
  • MAIT T-cell: 0.1 nTPM
  • memory B-cell: 0.1 nTPM
  • naive CD4 T-cell: 0.1 nTPM

Brain region

  • cerebellum: 13 nTPM
  • cerebral cortex: 12 nTPM
  • pons: 9.4 nTPM
  • medulla oblongata: 6.9 nTPM
  • thalamus: 6.7 nTPM
  • white matter: 5.1 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about FGF9.

Disease | AllUniProt

Conditions FGF9 is implicated in, by any mechanism.

Disease | GeneticClinVar

5 pathogenic / likely-pathogenic of 155 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Multiple synostoses syndrome 3

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.32
gnomAD pLI
0.95
gnomAD missense Z
1.54
DepMap mean gene effect
0.05
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FGF9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FGF9 as an antibody target. Whether an autoantibody or antibody against FGF9 could matter depends on whether native FGF9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FGF9 is annotated as secreted, so native FGF9 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label FGF9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/FGF9. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...